Trevi Therapeutics (NASDAQ:TRVI) Given New $28.00 Price Target at JonesTrading

Posted by Stanley Muller on Aug 14th, 2026

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) had its price objective raised by investment analysts at JonesTrading from $24.00 to $28.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. JonesTrading’s target price suggests a potential upside of 54.27% from the stock’s current price.

Other equities research analysts have also issued reports about the company. Oppenheimer upped their price objective on Trevi Therapeutics from $24.00 to $25.00 and gave the stock an “outperform” rating in a research note on Friday, August 7th. Wall Street Zen cut Trevi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday, May 20th. B. Riley Financial boosted their price objective on Trevi Therapeutics from $21.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Finally, Stifel Nicolaus set a $30.00 target price on shares of Trevi Therapeutics in a research note on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $27.08.

Read Our Latest Stock Report on TRVI

Trevi Therapeutics Stock Up 2.4%

Shares of NASDAQ:TRVI opened at $18.15 on Friday. The stock has a market capitalization of $2.59 billion, a PE ratio of -53.38 and a beta of 1.03. The firm’s 50 day moving average price is $17.30 and its 200-day moving average price is $14.24. Trevi Therapeutics has a twelve month low of $6.93 and a twelve month high of $20.22.

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). Analysts expect that Trevi Therapeutics will post -0.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Hilton Head Capital Partners LLC boosted its stake in Trevi Therapeutics by 32.6% in the 1st quarter. Hilton Head Capital Partners LLC now owns 4,250 shares of the company’s stock worth $51,000 after purchasing an additional 1,044 shares during the period. AlphaCentric Advisors LLC raised its position in shares of Trevi Therapeutics by 5.7% during the first quarter. AlphaCentric Advisors LLC now owns 23,970 shares of the company’s stock valued at $286,000 after buying an additional 1,303 shares during the last quarter. Kennedy Capital Management LLC raised its position in shares of Trevi Therapeutics by 2.4% during the fourth quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company’s stock valued at $704,000 after buying an additional 1,336 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Trevi Therapeutics by 32.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock worth $78,000 after acquiring an additional 1,523 shares during the last quarter. Finally, Oppenheimer & Co. Inc. grew its stake in Trevi Therapeutics by 2.1% during the fourth quarter. Oppenheimer & Co. Inc. now owns 100,698 shares of the company’s stock valued at $1,261,000 after acquiring an additional 2,030 shares in the last quarter. 95.76% of the stock is owned by hedge funds and other institutional investors.

About Trevi Therapeutics

(Get Free Report)

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.